quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:05:36·30d
SECFiling
TELA Bio Inc. logo

TELA Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

TELA· TELA Bio Inc.
Health Care
Original source

Companies

  • TELA
    TELA Bio Inc.
    Health Care

Recent analyst ratings

  • Mar 21UpdatePiper Sandler$2.00
  • May 31UpdateLake Street$17.00

Related

  • PR2d
    TELA Bio to Announce First Quarter 2026 Financial Results
  • SEC29d
    SEC Form S-8 filed by TELA Bio Inc.
  • SEC29d
    SEC Form 10-K filed by TELA Bio Inc.
  • PR30d
    TELA Bio Reports Fourth Quarter and Full Year 2025 Financial Results
  • SEC34d
    TELA Bio Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
  • INSIDER43d
    New insider Langstein Howard N. claimed ownership of 71,347 shares (SEC Form 3)
  • PR44d
    TELA Bio to Announce Fourth Quarter and Full Year 2025 Financial Results
  • INSIDER58d
    Chief Executive Officer Koblish Antony was granted 176,000 shares and covered exercise/tax liability with 28,025 shares, decreasing direct ownership by 0.66% to 586,210 units (SEC Form 4)
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022